Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 May 14;38(19):1509-1516.
doi: 10.1093/eurheartj/ehx032.

Anticoagulation for pregnant women with mechanical heart valves: a systematic review and meta-analysis

Rohan D'Souza  1   2 , Jackie Ostro  3 , Prakesh S Shah  2   4 , Candice K Silversides  5 , Ann Malinowski  1 , Kellie E Murphy  1   2 , Mathew Sermer  1 , Nadine Shehata  2   6
Affiliations
Meta-Analysis

Anticoagulation for pregnant women with mechanical heart valves: a systematic review and meta-analysis

Rohan D'Souza et al. Eur Heart J. .

Abstract

Aims: To review maternal and foetal outcomes in women with mechanical heart valves (MHVs) treated with vitamin-K antagonists (VKAs), first-trimester heparin followed by VKAs (sequential treatment), low molecular weight heparin (LMWH) and unfractionated heparin (UFH) during pregnancy, in order to inform practice.

Methods and results: Medline, Embase and Central were searched from inception until February 2016. Two reviewers independently screened 1786 titles, reviewed 110 full-texts and extracted data and assessed risk-of-bias from 46 articles. Pooled incidence (95% confidence intervals) was calculated for maternal and foetal outcomes. Included studies had a moderate or high risk-of-bias. With VKAs, sequential treatment and LMWH, maternal mortality occurred in 0.9% (0.4-1.4), 2.0% (0.8-3.1) and 2.9% (0.2-5.7), thromboembolic complications in 2.7% (1.4-4.0), 5.8% (3.8-7.7) and 8.7% (3.9-13.4), livebirths in 64.5% (48.8-80.2), 79.9% (74.3-85.6) and 92.0% (86.1-98.0) and anticoagulant-related foetal/neonatal adverse events (embryopathy or foetopathy) in 2.0% (0.3-3.7), 1.4% (0.3-2.5) and 0%, respectively. When UFH is used throughout pregnancy, 11.2% (2.8-19.6) suffered thromboembolic complications. Foetal loss and adverse events occurred with first-trimester warfarin doses ≤ 5 mg/day, although there were more livebirths [83.6% (75.8-91.4) vs. 43.9% (32.8-55.0)] and fewer foetal anomalies [2.3% (0.7-4.0) vs. 12.4% (3.3-21.6)] with lower doses than with warfarin > 5 mg/day.

Conclusions: VKAs are associated with fewest maternal complications but also with fewest livebirths. Sequential treatment does not eliminate anticoagulant-related foetal/neonatal adverse events. LMWH is associated with the highest number of livebirths. The safety of UFH throughout pregnancy and first-trimester warfarin ≤ 5 mg/day remains unconfirmed.

Keywords: Anticoagulation; Heparin; Mechanical heart valves; Pregnancy; Vitamin-K antagonists.

PubMed Disclaimer

Figures

Figure 1
Figure 1
PRISMA Diagram: Of the 1786 publications identified through the literature search and five through citation tracking, 110 were selected for full-text review and 46 were included in the analysis .
See this image and copyright information in PMC

Comment in

References

    1. Pibarot P, Dumesnil JG.. Prosthetic heart valves: selection of the optimal prosthesis and long-term management. Circulation 2009;119:1034–1048. - PubMed
    1. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA, O’Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM, Thomas JD, ACC/AHA Task Force Members 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American college of cardiology/American Heart Association task force on practice guidelines. Circulation 2014;129:e521–643. - PubMed
    1. Lawley CM, Lain SJ, Algert CS, Ford JB, Figtree GA, Roberts CL.. Prosthetic heart valves in pregnancy, outcomes for women and their babies: a systematic review and meta-analysis. BJOG 2015;122:1446–1455. - PubMed
    1. van Hagen IM, Roos-Hesselink JW, Ruys TP, et al. Pregnancy in women with a mechanical heart valve: data of the European society of cardiology registry of pregnancy and cardiac disease (ROPAC). Circulation 2015;132:132–142. - PubMed
    1. Chan WS, Anand S, Ginsberg JS.. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Int Med 2000;160:191–196. - PubMed